The Combined Effect of Triple Therapy with Rosiglitazone, Metformin, and Insulin Aspart in type 2 Diabetic Patients

Diabetes Care

Volumn 26, Issue 12, 2003, Pages 3273-3279

  Poulsen, Mikael Kjær ^a   Henriksen, Jan Erik ^a   Hother Nielsen, Ole ^a   Beck Nielsen, Henning ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; RANDOMIZATION; REDUCTION; SKELETAL MUSCLE;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; C-PEPTIDE; CIRCADIAN RHYTHM; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCOLYSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES;

EID: 0344412851     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.12.3273     Document Type: Article

References (27)

1. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U. S. population aged 20-74 yr. Diabetes 36:523-534, 1987
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
4. American Diabetes Association: Implications of the United Kingdom Prospective Diabetes Study (Position Statement). 25: S28-S32, 2002
5. Liebl A, Mata M, Eschwege E: Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 45:S23-S28, 2002
6. Yki-Jarvinen H: Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758-767, 2001
7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
8. Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
9. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
10. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states: sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94:1714-1721, 1994
11. Staehr P, Hother-Nielsen O, Levin K, Holst JJ, Beck-Nielsen H: Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes 50:1363-1370, 2001
12. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Reviews 6:89-131, 1998
13. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467-472, 2000
14. Insulin aspart. Asp-B28, NovoRapid. Drugs RD 2:103-106, 1999
15. Hother-Nielsen O, Beck-Nielsen H: On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia 33:603-610, 1990
16. Hother-Nielsen O, Mengel A, Moller J, Rasmussen O, Schmitz O, Beck-Nielsen H: Assessment of glucose turnover rates in euglycaemic clamp studies using primed-constant [3-3H]-glucose infusion and labelled or unlabelled glucose infusates. Diabet Med 9:840-849, 1992
17. Hother-Nielsen O, Henriksen JE, Staehr P, Beck-Nielsen H: Labelled glucose infusate technique in clamp studies: is precise matching of glucose specific activity important? Endocrinology and Metabolism 2:275-287, 1995
18. Markela E, Stahlberg TH, Hemmila I: Europium-labelled recombinant protein G: a fast and sensitive universal immunoreagent for time-resolved immunofluorometry. J Immunol Methods 161:1-6, 1993
19. Andersen L, Jorgensen PN, Jensen LB, Walsh D: A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 33:627-633, 2000
20. Itaya K, Ui M: Colorimetric determination of free fatty acids in biological fluids. J Lipid Res 6:16-20, 1965
21. Cowan JS, Hetenyi G Jr: Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 20:360-372, 1971
22. Insel PA, Linjenquist JE, Tobin JD, Sher-Win RS, Watkins P, Andres R, Berman M: Insulin control of glucose metabolism in man: a kinetic analysis. J Clin Invest 55:1057-1066, 1975
23. Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130-1136, 2000
24. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE: Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18:1183-1186, 1995
25. Bastyr EJ III, Johnson ME, Trautmann ME, Anderson JH Jr, Vignati L: Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 21:1703-1714, 1999
26. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
27. Beck-Nielsen H, Hother-Nielsen O, Staehr P: Is hepatic glucose production increased in type 2 diabetes mellitus. Curr Diab Rep 2:231-236, 2002